Non-CF bronchiectasis is a multifactorial disease involving various complex causes and a range of severity. The development and progression of bronchiectasis involve a vicious cycle of recurrent infection, inflammation, and structural damage to the airways. Due to the similarity of the symptoms with other pulmonary conditions, bronchiectasis is underdiagnosed. In addition, in some cases, patients may be asymptomatic but present with radiologic changes. The diagnosis of bronchiectasis now relies on high-resolution computed tomography (HRCT) evidence of dilated airways. To ensure that patients with bronchiectasis receive proper treatment early, it is crucial that radiologists can differentiate bronchiectasis patterns on HRCT to refine differential diagnosis and identify potential underlying etiologies.
Non-CF Bronchiectasis: How Radiologists Can Drive Better Outcomes
How well can you differentiate bronchiectasis patterns on imaging? Join our experts in this engaging case-based symposium and refine your skills.
United States
This broadcast will start in exactly:
- 0
Day(s)
- 0
Hour(s)
- 0
Minute(s)
- 0
Second(s)
Overview
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Chair:
Robert D. Suh, MD
Clinical Professor, Radiological Sciences
Ronald Regan UCLA Medical Center
Santa Monica, CADr. Suh has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Boehringer Ingelheim, Boston Scientific, Galvanize Therapeutics, NeuWise Medical
Faculty:
Lea Azour, MD
Associate Professor, Cardiothoracic Imaging
Director of Wellbeing, Dept. of Radiological Sciences
David Geffen School of Medicine at UCLA
Santa Monica, CA
Dr. Azour has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Siemens Healthineers
Ashwin Basavaraj, MD
Associate Professor of Medicine
NYU Grossman School of Medicine
New York, NY
Dr. Basavaraj has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: Baxter, MannKind
Reviewers/Content Planners/Authors:- Cindy Davidson has no relevant relationships to disclose.
- Wilma Guerra has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Describe the impact of untreated bronchiectasis on patient morbidity and healthcare utilization to underscore the need for timely intervention
- Accurately identify subtle imaging signs of bronchiectasis on high-resolution CT (HRCT) to facilitate early diagnosis and intervention
- Differentiate bronchiectasis patterns on HRCT to refine differential diagnosis and identify potential underlying etiologies
- Demonstrate effective communication strategies within the multidisciplinary team to ensure cohesive patient management and improved outcomes
Target Audience
This activity has been designed to meet the educational needs of radiologists and pulmonologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with non-CF bronchiectasis.
Accreditation and Credit Designation Statements
Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour(s)/0.1 CEUs of pharmacy contact hour(s).
The Universal Activity Number for this program is JA0006235-0000-25-046-L01-P. This learning activity is application-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).
Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit(s). PAs should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.Commercial Support
This activity is supported by an educational grant from Insmed.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Overview
Non-CF bronchiectasis is a multifactorial disease involving various complex causes and a range of severity. The development and progression of bronchiectasis involve a vicious cycle of recurrent infection, inflammation, and structural damage to the airways. Due to the similarity of the symptoms with other pulmonary conditions, bronchiectasis is underdiagnosed. In addition, in some cases, patients may be asymptomatic but present with radiologic changes. The diagnosis of bronchiectasis now relies on high-resolution computed tomography (HRCT) evidence of dilated airways. To ensure that patients with bronchiectasis receive proper treatment early, it is crucial that radiologists can differentiate bronchiectasis patterns on HRCT to refine differential diagnosis and identify potential underlying etiologies.
Disclosure of Conflicts of Interest
In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.
Chair:
Robert D. Suh, MD
Clinical Professor, Radiological Sciences
Ronald Regan UCLA Medical Center
Santa Monica, CADr. Suh has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Boehringer Ingelheim, Boston Scientific, Galvanize Therapeutics, NeuWise Medical
Faculty:
Lea Azour, MD
Associate Professor, Cardiothoracic Imaging
Director of Wellbeing, Dept. of Radiological Sciences
David Geffen School of Medicine at UCLA
Santa Monica, CA
Dr. Azour has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Consulting Fees: Siemens Healthineers
Ashwin Basavaraj, MD
Associate Professor of Medicine
NYU Grossman School of Medicine
New York, NY
Dr. Basavaraj has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
Research: Baxter, MannKind
Reviewers/Content Planners/Authors:- Cindy Davidson has no relevant relationships to disclose.
- Wilma Guerra has no relevant relationships to disclose.
- Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose.
Learning Objectives
Upon completion of this activity, learners should be better able to:
- Describe the impact of untreated bronchiectasis on patient morbidity and healthcare utilization to underscore the need for timely intervention
- Accurately identify subtle imaging signs of bronchiectasis on high-resolution CT (HRCT) to facilitate early diagnosis and intervention
- Differentiate bronchiectasis patterns on HRCT to refine differential diagnosis and identify potential underlying etiologies
- Demonstrate effective communication strategies within the multidisciplinary team to ensure cohesive patient management and improved outcomes
Target Audience
This activity has been designed to meet the educational needs of radiologists and pulmonologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with non-CF bronchiectasis.
Accreditation and Credit Designation Statements
Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour(s)/0.1 CEUs of pharmacy contact hour(s).
The Universal Activity Number for this program is JA0006235-0000-25-046-L01-P. This learning activity is application-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net).Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit(s). PAs should claim only the credit commensurate with the extent of their participation in the activity.
Provider(s)/Educational Partner(s)
Prova Education designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties. Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the best education in the most impactful manner and to verify its results with progressive outcomes research.Commercial Support
This activity is supported by an educational grant from Insmed.
Disclaimer
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Reproduction Prohibited
Reproduction of this material is not permitted without written permission from the copyright owner.System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Recommended
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?